Miricorilant

In today's world, Miricorilant is a topic of great relevance and continues to generate constant debate among experts and people interested in the topic. For many years now, Miricorilant has captured the attention of society in general, whether due to its impact on daily life, its importance in history, or its relevance in the current environment. Over the years, Miricorilant has been the subject of numerous studies and analyzes that have yielded surprising results and unexpected conclusions. In this article, we will thoroughly explore the topic of Miricorilant and examine its influence on different aspects of today's society.

Miricorilant
Clinical data
Other namesCORT 118335
Legal status
Legal status
  • Investigational
Identifiers
  • 6-(4-phenylcyclohexyl)-5-methyl]-1H-pyrimidine-2,4-dione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
KEGG
ChEMBL
Chemical and physical data
FormulaC24H23F3N2O2
Molar mass428.455 g·mol−1
3D model (JSmol)
  • C1CC(CCC1C2=CC=CC=C2)C3=C(C(=O)NC(=O)N3)CC4=CC(=CC=C4)C(F)(F)F
  • InChI=1/C24H23F3N2O2/c25-24(26,27)19-8-4-5-15(13-19)14-20-21(28-23(31)29-22(20)30)18-11-9-17(10-12-18)16-6-2-1-3-7-16/h1-8,13,17-18H,9-12,14H2,(H2,28,29,30,31)/t17-,18-
  • Key:GVVUZBSCYAVFTI-IYARVYRRNA-N

Miricorilant (CORT 118335) is a small molecule that works as a selective glucocorticoid receptor modulator and mineralcorticoid receptor antagonist. It was developed by Corcept Therapeutics for nonalcoholic steatohepatitis and weight gain associated with atypical antipsychotics.

References

  1. ^ Mammi, C.; Marzolla, V.; Armani, A.; Feraco, A.; Antelmi, A.; Maslak, E.; Chlopicki, S.; Cinti, F.; Hunt, H.; Fabbri, A.; Caprio, M. (June 2016). "A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet". International Journal of Obesity. 40 (6): 964–972. doi:10.1038/ijo.2016.13. ISSN 1476-5497. PMID 26830012. S2CID 19751493.
  2. ^ Nguyen, Elizabeth T.; Berman, Sarah; Streicher, Joshua; Estrada, Christina M.; Caldwell, Jody L.; Ghisays, Valentina; Ulrich-Lai, Yvonne; Solomon, Matia B. (1 August 2019). "Effects of combined glucocorticoid/mineralocorticoid receptor modulation (CORT118335) on energy balance, adiposity, and lipid metabolism in male rats". American Journal of Physiology. Endocrinology and Metabolism. 317 (2): E337–E349. doi:10.1152/ajpendo.00018.2019. PMID 31112405. S2CID 162170330.
  3. ^ Nguyen, Elizabeth T.; Caldwell, Jody L.; Streicher, Joshua; Ghisays, Valentina; Balmer, Nikolaus J.; Estrada, Christina M.; Solomon, Matia B. (January 2018). "Differential effects of imipramine and CORT118335 (Glucocorticoid receptor modulator/mineralocorticoid receptor antagonist) on brain-endocrine stress responses and depression-like behavior in female rats". Behavioural Brain Research. 336: 99–110. doi:10.1016/j.bbr.2017.08.045. PMID 28866130. S2CID 5511661.
  4. ^ Koorneef, Lisa L; van den Heuvel, José K; Kroon, Jan; Boon, Mariëtte R; ’t Hoen, Peter A C; Hettne, Kristina M; van de Velde, Nienke M; Kolenbrander, Kelsey B; Streefland, Trea C M; Mol, Isabel M; Sips, Hetty C M; Kielbasa, Szymon M; Mei, Hailiang; Belanoff, Joseph K; Pereira, Alberto M; Oosterveer, Maaike H; Hunt, Hazel; Rensen, Patrick C N; Meijer, Onno C (12 October 2018). "Selective glucocorticoid receptor modulation prevents and reverses non-alcoholic fatty liver disease in male mice". Endocrinology. 159 (12): 3925–3936. doi:10.1210/en.2018-00671. hdl:1887/79939. PMID 30321321. S2CID 53501584.
  5. ^ Hunt, Hazel J.; Donaldson, Kirsteen; Strem, Mark; Tudor, Iulia Cristina; Sweet-Smith, Suzanne; Sidhu, Sharan (November–December 2021). "Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects: A Proof-of-Concept Study". Journal of Clinical Psychopharmacology. 41 (6): 632–637. doi:10.1097/JCP.0000000000001470. ISSN 1533-712X. PMC 8575171. PMID 34369902.
Wikious
Boobota
Sagapedia